Jenny Harry - Neuren Pharmaceuticals Non-Executive Independent Director
NURPF Stock | USD 12.53 0.00 0.00% |
Director
Dr. Jenny Lee Harry is NonExecutive Independent Director of the Company. Dr Jenny Harry is currently CEO of drug development company Ondek and was formerly CEO and Managing Director of Tyrian Diagnostics, leading its transformation and the commercialisation of its first diagnostic product. since 2018.
Tenure | 6 years |
Professional Marks | Ph.D |
Phone | 61 3 9092 0480 |
Web | https://www.neurenpharma.com |
Neuren Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.172) % which means that it has lost $0.172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2746) %, meaning that it generated substantial loss on money invested by shareholders. Neuren Pharmaceuticals' management efficiency ratios could be used to measure how well Neuren Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Mason Freeman | Crinetics Pharmaceuticals | 66 | |
Alan Lewis | Assembly Biosciences | 71 | |
Veena Hingarh | Instil Bio | N/A | |
John Rickard | Instil Bio | N/A | |
Edward Myles | Scholar Rock Holding | 46 | |
Helen Kim | Assembly Biosciences | 54 | |
Roger Loeb | Instil Bio | N/A | |
George Rohlinger | Instil Bio | N/A | |
Gaurav Swarup | Instil Bio | 60 | |
Jeffrey Flier | Scholar Rock Holding | 70 | |
Richard Flavell | Cerevel Therapeutics Holdings | 71 | |
Yutaka Kobayashi | MediciNova | 54 | |
Aloke Banerjee | Instil Bio | 61 | |
Geoffrey Swier | Instil Bio | N/A | |
Daniel Mendelson | Champions Oncology | 52 | |
Susan Mahony | Assembly Biosciences | 52 | |
Anthony Altig | Assembly Biosciences | 61 | |
Kristina Burow | Scholar Rock Holding | 44 | |
Weston Nichols | Crinetics Pharmaceuticals | 32 | |
Wayne Kauth | Instil Bio | 79 | |
Phillip Strachan | Instil Bio | N/A |
Management Performance
Return On Equity | -0.27 | |||
Return On Asset | -0.17 |
Neuren Pharmaceuticals Leadership Team
Elected by the shareholders, the Neuren Pharmaceuticals' board of directors comprises two types of representatives: Neuren Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuren. The board's role is to monitor Neuren Pharmaceuticals' management team and ensure that shareholders' interests are well served. Neuren Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuren Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph Horrigan, VP of Clinical Devel. and Medical Affairs | ||
Larry Glass, CEO, Managing Director | ||
Bruce Hancox, Independent Non-Executive Director | ||
James Shaw, COO | ||
Patrick Davies, Non-Executive Independent Director | ||
Lauren CA, CFO Sec | ||
Richard Treagus, Executive Chairman of the Board | ||
Jon Pilcher, CFO, Company Secretary | ||
Jenny Harry, Non-Executive Independent Director | ||
Dianne Angus, Non-Executive Independent Director | ||
ACA ACA, MD CEO | ||
Gerry Zhao, VP Devel | ||
Liza MD, Chief Officer | ||
Trevor Scott, Independent Non-Executive Director | ||
Lawrence Glass, Chief Officer |
Neuren Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Neuren Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.27 | |||
Return On Asset | -0.17 | |||
Profit Margin | (2.15) % | |||
Operating Margin | (2.31) % | |||
Current Valuation | 602.02 M | |||
Shares Outstanding | 128.97 M | |||
Shares Owned By Insiders | 16.48 % | |||
Shares Owned By Institutions | 9.41 % | |||
Price To Earning | 49.75 X | |||
Price To Book | 27.96 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Neuren Pink Sheet analysis
When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |